Welcome to IgMin Research – an Open Access journal uniting Biology, Medicine, and Engineering. We’re dedicated to advancing global knowledge and fostering collaboration across scientific fields.
At IgMin Research, we bridge the frontiers of Biology, Medicine, and Engineering to foster interdisciplinary innovation. Our expanded scope now embraces a wide spectrum of scientific disciplines, empowering global researchers to explore, contribute, and collaborate through open access.
Welcome to IgMin, a leading platform dedicated to enhancing knowledge dissemination and professional growth across multiple fields of science, technology, and the humanities. We believe in the power of open access, collaboration, and innovation. Our goal is to provide individuals and organizations with the tools they need to succeed in the global knowledge economy.
IgMin Publications Inc., Suite 102, West Hartford, CT - 06110, USA
We promote fostering alliances across disciplines to catalyze the rapid development of ideas.
Biography
Dr. Ayisha Farooq Khan is a distinguished neurologist affiliated with the Section of Neurology, Department of Medicine at Aga Khan University (AKU), Karachi, PakistanShe earned her medical training and specialization in neurology at AKU, where she now serves as a consultant neurologist specializing in clinical neurophysiology and patient care.
Throughout her career, Dr. Khan has developed a robust scholarly portfolio, publishing in both peer-reviewed and open-access venues. Her groundbreaking case report in 2024, “Levetiracetam‑induced Rhabdomyolysis – A Rare Complication,” co‑authored with Naeemuddin Shaikh and colleagues, highlights her commitment to illuminating underrecognized neurologic drug reactionsAnother notable contribution includes a 2025 article in Archives of Iranian Medicine on Epstein‑Barr Virus encephalitis presenting as status epilepticus—underscoring her dedication to identifying rare but critical neurologic emergencies. Her body of work encompasses a wide clinical spectrum—from Guillain–Barré syndrome secondary to dengue, CVT following inactivated‑virus COVID‑19 vaccination, to insights into EEG abnormalities in COVID‑19 and outcomes of epilepsy surgery in Pakistan.
An active participant in multidisciplinary neurology research at AKU, Dr. Khan has co-authored studies in electrodiagnostics, neuroinflammatory disorders, sleep medicine, and cerebrovascular neurology. Beyond clinical duties, she contributes to advancing practice standards at AKU and has been recognized for academic excellence, including being featured on ResearchGate with numerous citations .
In clinical practice, Dr. Khan is valued for her expertise in diagnostic neurophysiology, cerebral venous thrombosis, and drug‑induced neurologic complications. Her commitment to patient care, combined with ongoing research endeavors, positions her as a rising authority in neurology within both Pakistan and international scientific circles.
Research Interest
Dr. Ayisha Farooq Khan’s research interests lie at the intersection of clinical neurology, neurophysiology, and neuroinfectious diseases. She is particularly focused on exploring rare neurological complications arising from medications, such as drug-induced rhabdomyolysis and immune-mediated neuropathies. Her work also investigates the neurological manifestations of infectious agents, including Epstein–Barr Virus encephalitis and neurological syndromes secondary to dengue and COVID-19. Dr. Khan has a strong interest in cerebral venous thrombosis (CVT), epilepsy surgery outcomes, and the use of EEG in critically ill patients. She actively contributes to improving diagnostic protocols in neurology, especially in resource-limited settings. In addition to clinical research, she is engaged in understanding the broader implications of neurological diseases on public health in Pakistan. Her multidisciplinary approach combines clinical case insights, epidemiological analysis, and collaborative research to address gaps in neurology education, diagnosis, and patient care in South Asia. Dr. Khan continues to contribute significantly to advancing neurological sciences at Aga Khan University.
Open Access Policy refers to a set of principles and guidelines aimed at providing unrestricted access to scholarly research and literature. It promotes the free availability and unrestricted use of research outputs, enabling researchers, students, and the general public to access, read, download, and distribute scholarly articles without financial or legal barriers. In this response, I will provide you with an overview of the history and latest resolutions related to Open Access Policy.
byAyisha Farooq Khan, Naeemuddin Shaikh, Faryal Abdy and Dureshahwar Kanwar
Background: Levetiracetam is an anti-epileptic drug that works by modulation of synaptic neurotransmitter release through binding to the synaptic vesicle protein 2A. Levetiracetam is generally well tolerated. Common side effects of levetiracetam include lethargy, drowsiness, headaches, and mood changes. Rhabdomyolysis and an increase in Creatine Kinase (CK) levels are one of the rarely reported effects of levetiracetam.Case presentation: We present a case of a 20-year-old patient with previously known epilepsy (non-compliant with medicine) who ...presented with a seizure. The patient was given 1 gram of levetiracetam in the emergency department and was kept at a maintenance dose of 500 mg twice a day. The workup revealed acute kidney injury and raised levels of creatinine kinase that peaked at 19,757 IU/L 72 hours after levetiracetam was started. Levetiracetam was later switched to lamotrigine and aggressive intravenous hydration was done. Gradual improvement of CK level was noted accompanied by improvement in renal function.Conclusion: Only a few cases of levetiracetam-induced rhabdomyolysis have been reported worldwide. Our case report highlights the importance of monitoring creatinine and CK levels while treating patients with levetiracetam as rhabdomyolysis can be asymptomatic with a rise in CK levels only.
0000-0003-2771-0072 
